Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

2021186 citationsJournal Articlebronze Open Access

Authors

Junzo Hamanishi · Kyoto University

Nobuhiro Takeshima · The Cancer Institute Hospital

Noriyuki Katsumata · Nippon Medical School

Kimio Ushijima · Kurume University

Tadashi Kimura · The University of Osaka

Satoshi Takeuchi · Iwate Medical University

Koji Matsumoto · Hyogo Prefectural Cancer Center

Kimihiko Ito

Abstract

Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer.

Topics & Keywords

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Cancer Immunotherapy and Biomarkers

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 33, pp. 3671-3681

DOI: 10.1200/jco.21.00334

Field-Weighted Citation Impact: 23.89

Command Palette

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Authors

Abstract

Topics & Keywords

Publication Details